For over a decade, clinicians prescribing testosterone replacement therapy to older hypogonadal men have operated in an evidence vacuum—relying on underpowered trials and observational data that pointed in contradictory directions. A comprehensive systematic review now consolidates that fractured landscape, anchoring its conclusions around the landmark TRAVERSE trial and extending the analysis through 64 rigorously selected studies to offer the clearest cardiovascular risk picture to date.
The central finding is reassuring at the headline level: testosterone replacement therapy demonstrated non-inferiority to placebo for major adverse cardiovascular events (MACE) in hypogonadal men carrying elevated baseline cardiovascular risk, with a hazard ratio of 0.96 (95% CI 0.78–1.17). That confidence interval comfortably excludes clinically meaningful harm on the primary endpoint. However, the review draws careful attention to secondary signals that TRAVERSE was not powered to resolve. Numerically elevated rates of atrial fibrillation (3.1% vs. 2.4%), pulmonary embolism (2.0% vs. 1.5%), and acute kidney injury (2.3% vs. 1.5%) appeared in the TRT arm—none achieving statistical significance individually, yet collectively forming a pattern that warrants scrutiny in longer or larger follow-up data. The review also addresses a clinically underappreciated distinction between organic and functional hypogonadism, with differential management implications.
Placing this within the broader research landscape, TRAVERSE represents a genuine methodological step-change from prior evidence—adequately powered, randomized, and placebo-controlled. That said, the trial enrolled men already at elevated cardiovascular risk, limiting generalizability to healthier populations or younger hypogonadal men. The non-MACE signals, though non-significant, align with biologically plausible mechanisms: testosterone's effects on erythropoiesis could amplify thromboembolic risk, and its hemodynamic actions may stress vulnerable renal or atrial tissue. This review is confirmatory and synthesizing rather than paradigm-shifting, but its clinical value is considerable. The organic-versus-functional hypogonadism framework it advances deserves particular attention from prescribers, as treating functional hypogonadism—where low testosterone reflects systemic illness or lifestyle factors rather than primary gonadal failure—carries a distinct risk-benefit calculus that aggregate trial data can obscure.